
Cardio Diagnostic Holdings Announces New Lab for Proprietary Heart Disease Tests; Focused on Cost Reduction
Cardio Diagnostics Holdings, Inc (Nasdaq: CDIO), a provider of artificial intelligence-driven precision cardiovascular medical tests, has unveiled its state-of-the-art integrated facility in Iowa City, Iowa. This new facility serves as the nucleus for their research laboratory, high-complexity Clinical Laboratory Improvement Amendments (CLIA) laboratory, and a fulfillment center, all aimed at streamlining operations, reducing costs, improving efficiency, and ultimately enhancing patient outcomes.
Cardio Diagnostics sells two major products. The first test, PrecisionCHD™, is a diagnostic test designed to detect coronary heart disease. The test was developed using their AI-driven Integrated Genetic-Epigenetic Engine™ and validated in partnership with Intermountain Healthcare and University of Iowa Hospitals and Clinics. PrecisionCHD™ combines epigenetics, genetics, and artificial intelligence to provide an advanced assessment of CHD, the leading cause of heart attacks and the most prevalent form of heart disease. The company’s second test is Epi+Gen CHD™, a patented next generation test, which assesses an individual’s near-term (3-year) risk for a heart attack. The test uses distinct DNA biomarkers looking at genetic and epigenetic signals.
Scheduled to commence initial operations in Q4 2023, with full operations expected in Q1 2024, this facility marks a significant milestone in Cardio Diagnostics’ strategy of vertical integration. Dr. Meesha Dogan, CEO and Co-Founder of Cardio Diagnostics, highlighted the critical role this facility will play in accelerating research and development, centralizing sample kit distribution, scaling commercial testing, and reducing reliance on external service providers.
The high-complexity CLIA laboratory, with its modular setup, is capable of processing up to 10,000 tests monthly while significantly cutting down on laboratory processing costs, which currently form the largest segment of the cost of goods sold. Internal handling of sample collection kit fulfillment further slashes costs, improving overall operational efficiency.
Dr. Robert Philibert, Chief Medical Officer and Co-Founder of Cardio Diagnostics, emphasized that an in-house high-complexity CLIA lab will enable them to develop a testing process with a quick turnaround time of under 4 hours. The vision is to eventually offer heart disease diagnostic tests as point-of-care tests with a same-day turnaround, a significant step forward in global patient care.